Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review Source: Eur Respir J, 52 (1) 1800934; 10.1183/13993003.00934-2018 Year: 2018
Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Source: Eur Respir J 2009; 33: 871-881 Year: 2009
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study Source: Eur Respir J 2001; 18: 369-375 Year: 2001
The debacillisation rate during controlled anti-TB therapy Source: Annual Congress 2005 - Information for the active clinician Year: 2005
The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion Source: Eur Respir J 2015; 45: 1170-1173 Year: 2015
The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019